Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivastigmine and Scopolamine for Hallucinations
NCT04366518Phase 1Recruiting
- Sponsor
- Yale University
- Start
- Jul 2021
- Primary completion
- Aug 2032
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of rivastigmine, sponsored by Yale University. Primary endpoint: Number of conditioned hallucinations exhibited at 90 minutes. Started Jul 2021; status: recruiting.
02
Drugs
rivastigmine
Beyond the preview
Go deeper on NCT04366518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04366518.